https://www.selleckchem.com/products/ABT-263.html
Effective adjuvant therapeutic strategies are urgently needed to overcome MAPK inhibitor (MAPKi) resistance, which is one of the most common forms of resistance that has emerged in many types of cancers. Here, we aimed to systematically identify the genetic interactions underlying MAPKi resistance, and to further investigate the mechanisms that produce the genetic interactions that generate synergistic MAPKi resistance. We conducted a comprehensive pair-wise sgRNA-based high-throughput screening assay to identify synergistic interaction
Like
Comment
Share
